Cargando…

How Can a High-Performance Screening Strategy Be Determined for Cervical Cancer Prevention? Evidence From a Hierarchical Clustering Analysis of a Multicentric Clinical Study

BACKGROUND: This study aimed to explore the cluster patterns of cervical cancer screening strategies for detecting high-grade precancerous lesions in terms of benefits, costs, and efficiency. METHODS: A total of 2,065 referral women aged 25–64 years were recruited and underwent human papillomavirus...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Heling, Zhang, Xiaosong, Bi, Hui, Zhao, Yun, Fang, Liwen, Wang, Haijun, Wang, Linhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829547/
https://www.ncbi.nlm.nih.gov/pubmed/35155253
http://dx.doi.org/10.3389/fonc.2022.816789
_version_ 1784648106440130560
author Bao, Heling
Zhang, Xiaosong
Bi, Hui
Zhao, Yun
Fang, Liwen
Wang, Haijun
Wang, Linhong
author_facet Bao, Heling
Zhang, Xiaosong
Bi, Hui
Zhao, Yun
Fang, Liwen
Wang, Haijun
Wang, Linhong
author_sort Bao, Heling
collection PubMed
description BACKGROUND: This study aimed to explore the cluster patterns of cervical cancer screening strategies for detecting high-grade precancerous lesions in terms of benefits, costs, and efficiency. METHODS: A total of 2,065 referral women aged 25–64 years were recruited and underwent human papillomavirus (HPV) testing, liquid-based cytology with manual reading, and cytology with artificial intelligence (AI)-assisted reading. All women were assessed by colposcopy and histological examination. We formed 14 screening strategies based on primary cytology screening, primary HPV screening incorporating HPV-16/18 genotyping triage, cytology triage, or both, and co-testing. The primary outcomes were cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and grade 3 or worse (CIN3+). The hierarchical clustering method was applied to multifaceted indicators, and then, the resulting clusters were described in terms of benefits, costs, efficiency, and their interaction. This study was registered (No. ChiCTR2000034131). RESULTS: The relative sensitivity of HPV-based strategies compared with cytology alone with the threshold of LSIL+ ranged from 0.68 to 1.19 for CIN2+ detection and from 0.72 to 1.11 for CIN3+ detection, whereas the relative specificity ranged from 0.55 to 1.43 for CIN2+ detection and from 0.51 to 1.51 for CIN3+ detection. Five significant clusters according to the trade-off among benefits, costs, and efficiency were identified. The cluster including four primary HPV screening strategies showed the optimal balance. HPV testing with HPV-16/18 genotyping and AI-based cytology triage presented the optimal trade-off for CIN3+ detection relative to cytology alone in terms of relative sensitivity (1.06), relative specificity (0.72), colposcopies for 1 CIN3+ (3.7 vs. 3.1), a load of follow-up for women with HPV-positive and normal cytology (7.0% vs. 22.3%), and the work of manual cytology reading (35.1% vs. 100%). CONCLUSIONS: Our study provided clinical and methodological evidence on the choice of HPV-based screening strategies. The cluster including primary HPV screening with genotyping and cytology triage showed an optimal balance among benefit, cost, and efficiency.
format Online
Article
Text
id pubmed-8829547
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88295472022-02-11 How Can a High-Performance Screening Strategy Be Determined for Cervical Cancer Prevention? Evidence From a Hierarchical Clustering Analysis of a Multicentric Clinical Study Bao, Heling Zhang, Xiaosong Bi, Hui Zhao, Yun Fang, Liwen Wang, Haijun Wang, Linhong Front Oncol Oncology BACKGROUND: This study aimed to explore the cluster patterns of cervical cancer screening strategies for detecting high-grade precancerous lesions in terms of benefits, costs, and efficiency. METHODS: A total of 2,065 referral women aged 25–64 years were recruited and underwent human papillomavirus (HPV) testing, liquid-based cytology with manual reading, and cytology with artificial intelligence (AI)-assisted reading. All women were assessed by colposcopy and histological examination. We formed 14 screening strategies based on primary cytology screening, primary HPV screening incorporating HPV-16/18 genotyping triage, cytology triage, or both, and co-testing. The primary outcomes were cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and grade 3 or worse (CIN3+). The hierarchical clustering method was applied to multifaceted indicators, and then, the resulting clusters were described in terms of benefits, costs, efficiency, and their interaction. This study was registered (No. ChiCTR2000034131). RESULTS: The relative sensitivity of HPV-based strategies compared with cytology alone with the threshold of LSIL+ ranged from 0.68 to 1.19 for CIN2+ detection and from 0.72 to 1.11 for CIN3+ detection, whereas the relative specificity ranged from 0.55 to 1.43 for CIN2+ detection and from 0.51 to 1.51 for CIN3+ detection. Five significant clusters according to the trade-off among benefits, costs, and efficiency were identified. The cluster including four primary HPV screening strategies showed the optimal balance. HPV testing with HPV-16/18 genotyping and AI-based cytology triage presented the optimal trade-off for CIN3+ detection relative to cytology alone in terms of relative sensitivity (1.06), relative specificity (0.72), colposcopies for 1 CIN3+ (3.7 vs. 3.1), a load of follow-up for women with HPV-positive and normal cytology (7.0% vs. 22.3%), and the work of manual cytology reading (35.1% vs. 100%). CONCLUSIONS: Our study provided clinical and methodological evidence on the choice of HPV-based screening strategies. The cluster including primary HPV screening with genotyping and cytology triage showed an optimal balance among benefit, cost, and efficiency. Frontiers Media S.A. 2022-01-27 /pmc/articles/PMC8829547/ /pubmed/35155253 http://dx.doi.org/10.3389/fonc.2022.816789 Text en Copyright © 2022 Bao, Zhang, Bi, Zhao, Fang, Wang and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Bao, Heling
Zhang, Xiaosong
Bi, Hui
Zhao, Yun
Fang, Liwen
Wang, Haijun
Wang, Linhong
How Can a High-Performance Screening Strategy Be Determined for Cervical Cancer Prevention? Evidence From a Hierarchical Clustering Analysis of a Multicentric Clinical Study
title How Can a High-Performance Screening Strategy Be Determined for Cervical Cancer Prevention? Evidence From a Hierarchical Clustering Analysis of a Multicentric Clinical Study
title_full How Can a High-Performance Screening Strategy Be Determined for Cervical Cancer Prevention? Evidence From a Hierarchical Clustering Analysis of a Multicentric Clinical Study
title_fullStr How Can a High-Performance Screening Strategy Be Determined for Cervical Cancer Prevention? Evidence From a Hierarchical Clustering Analysis of a Multicentric Clinical Study
title_full_unstemmed How Can a High-Performance Screening Strategy Be Determined for Cervical Cancer Prevention? Evidence From a Hierarchical Clustering Analysis of a Multicentric Clinical Study
title_short How Can a High-Performance Screening Strategy Be Determined for Cervical Cancer Prevention? Evidence From a Hierarchical Clustering Analysis of a Multicentric Clinical Study
title_sort how can a high-performance screening strategy be determined for cervical cancer prevention? evidence from a hierarchical clustering analysis of a multicentric clinical study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829547/
https://www.ncbi.nlm.nih.gov/pubmed/35155253
http://dx.doi.org/10.3389/fonc.2022.816789
work_keys_str_mv AT baoheling howcanahighperformancescreeningstrategybedeterminedforcervicalcancerpreventionevidencefromahierarchicalclusteringanalysisofamulticentricclinicalstudy
AT zhangxiaosong howcanahighperformancescreeningstrategybedeterminedforcervicalcancerpreventionevidencefromahierarchicalclusteringanalysisofamulticentricclinicalstudy
AT bihui howcanahighperformancescreeningstrategybedeterminedforcervicalcancerpreventionevidencefromahierarchicalclusteringanalysisofamulticentricclinicalstudy
AT zhaoyun howcanahighperformancescreeningstrategybedeterminedforcervicalcancerpreventionevidencefromahierarchicalclusteringanalysisofamulticentricclinicalstudy
AT fangliwen howcanahighperformancescreeningstrategybedeterminedforcervicalcancerpreventionevidencefromahierarchicalclusteringanalysisofamulticentricclinicalstudy
AT wanghaijun howcanahighperformancescreeningstrategybedeterminedforcervicalcancerpreventionevidencefromahierarchicalclusteringanalysisofamulticentricclinicalstudy
AT wanglinhong howcanahighperformancescreeningstrategybedeterminedforcervicalcancerpreventionevidencefromahierarchicalclusteringanalysisofamulticentricclinicalstudy